http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105980397-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b416a8c0d2b0f1c3d6026d932027af |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D61-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34 |
| filingDate | 2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_569c2bb841af75ae224fdc9363dddea3 |
| publicationDate | 2016-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105980397-A |
| titleOfInvention | fractionation method |
| abstract | A method of purifying an IgG antibody from a preparation comprising providing said preparation in a form having significantly reduced chromatin levels as compared to that of a sample from which said preparation was obtained, and contacting said preparation with a positively charged membrane contact, the positively charged membrane has a porosity that retains at least 50% of unadsorbed solutes with a hydrodynamic diameter larger than the selected size, but allows a hydrodynamic diameter smaller than the selected size wherein the selected size is from about 10 nm to about 15 nm, wherein during at least a portion of the contacting step, the formulation comprises a salt such that (1) when present at a concentration of less than 50 mM , a pH in the range of about 3 to within 0.5 pH units of the isoelectric point of the most basic glycoform of said IgG antibody in said formulation; or (2) when present at a concentration greater than 50 mM, said The pH of the formulation ranges from 3 to 9; and the operating conditions are adjusted to the highest pH and lowest salt concentration that do not result in binding of more than 5% of the antibody to the membrane. |
| priorityDate | 2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.